Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

456.95 +6.15 (+1.36%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,050,979
Open 451.90
Bid (Size) 450.80 (1)
Ask (Size) 465.45 (1)
Prev. Close 450.80
Today's Range 449.42 - 457.66
52wk Range 335.82 - 457.66
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Got $500? 3 Pharma Stocks to Buy and Hold Forever
These players might even beat the market when the conditions are right. 
Via The Motley Fool
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Shares of the growing biotech company have doubled in three years. 
Via The Motley Fool

Performance

YTD
+11.20%
+11.20%
1 Month
+14.02%
+14.02%
3 Month
+6.24%
+6.24%
6 Month
+29.43%
+29.43%
1 Year
+30.87%
+30.87%

More News

Read More
2 Biotech Stocks to Buy in May
Via The Motley Fool
3 High-Flying Stocks That Could Soar Even More
Via The Motley Fool
Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity
Via Benzinga
SLB, First Solar And 2 Other Stocks Insiders Are Selling
Via Benzinga
Should you consider NASDAQ:VRTX for quality investing?
Via Chartmill
Vertex Pharmaceuticals's Options Frenzy: What You Need to Know
Via Benzinga
A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics
Via Benzinga
Walmart, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'
Via Benzinga
The 2030 Millionaire’s Club: 3 Biotech Stocks to Buy Now
Via InvestorPlace
Vertex to Participate in Upcoming June Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating
Via Investor's Business Daily
Is CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So.
Via The Motley Fool
Jennifer Schneider Elected to Vertex Board of Directors
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals And A Major Tech Stock On CNBC's 'Final Trades'
Via Benzinga
Exposures COVID-19
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
Via Investor's Business Daily
3 Cheap Biotech Stocks to Buy Now: May 2024
Via InvestorPlace
Exposures Product Safety
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years
Via Benzinga
Vertex Pharmaceuticals Is Racing Towards a New Blockbuster: Why the Stock Is a Smart Buy
Via The Motley Fool
2 Unbelievable Growth Stocks You Can Buy and Hold for the Next Decade
Via The Motley Fool
Stock Market Moves Toward Highs; Arista, Toast, Palantir Key Earnings Movers: Weekly Review
Via Investor's Business Daily
Will the Biotech Sector Shift From Lagger to Leader?
Via MarketBeat
Topics ETFs
Investors seeking growth at a reasonable cost should explore NASDAQ:VRTX.
Via Chartmill
5 Reasons Vertex Pharmaceuticals Is a Screaming Buy on the Dip
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.